Drug
Plg0206
Plg0206: highest development phase Phase 2/3, developed by Peptilogics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Peptilogics
Trials
| Drug | Phase | Indication |
|---|---|---|
| PLG0206 NCT07214311 | Phase 2/3 | Prosthetic-joint Infection |
Latest
No recent events.
Follow Plg0206 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.